CagriSema: Novo Nordisk's 22.7% Weight Loss Drug Explained
CagriSema combines cagrilintide (amylin) and semaglutide in a single weekly injection. FDA review is underway. Here is what patients need to know about this new drug.
CagriSema is Novo Nordisk's most ambitious new obesity drug. It combines two separate hormone-targeting mechanisms in a single weekly injection - and Phase 3 data shows it significantly outperforms either component on its own.
The FDA has been reviewing the application since December 2025.
What is CagriSema?
CagriSema is a fixed-dose combination injection containing:
- Cagrilintide 2.4 mg - a long-acting amylin analogue (investigational)
- Semaglutide 2.4 mg - the same GLP-1 agonist in Wegovy (already approved)
It is given as a once-weekly subcutaneous injection, the same format as Wegovy and Mounjaro.
The combination is significant because amylin and GLP-1 suppress appetite through different pathways - they work on different brain regions and different receptors. Activating both simultaneously produces a stronger and more complementary effect than either hormone alone.
What is amylin, and why does it matter?
Amylin is a hormone produced by the same pancreatic cells that produce insulin. It is released after meals and works alongside insulin to regulate blood sugar and appetite. Its effects include:
- Slowing gastric emptying (food stays in the stomach longer)
- Suppressing glucagon (reduces blood sugar spikes after meals)
- Signalling satiety through the hypothalamus and brainstem
A drug called pramlintide (Symlin) has existed as an amylin analogue for diabetes since 2005, but it required three daily injections and was impractical. Cagrilintide is a long-acting version designed specifically for once-weekly use.
What do the Phase 3 REDEFINE trials show?
Novo Nordisk ran a comprehensive Phase 3 program under the REDEFINE name.
REDEFINE 1 (Key pivotal trial - obesity without diabetes)
- 3,417 adults with obesity or overweight plus at least one comorbidity
- 68 weeks
- CagriSema: 22.7% average weight loss
- Semaglutide 2.4 mg alone: 16.1%
- Cagrilintide 2.4 mg alone: 11.8%
- Placebo: 2.3%
- This trial was the basis for the NDA submission to the FDA
REDEFINE 2 (Obesity + type 2 diabetes)
- 1,200 adults, 68 weeks
- CagriSema: 15.7% average weight loss vs 3.1% placebo
- 89.7% of patients achieved at least 5% weight loss
REDEFINE 4 (Head-to-head vs Tirzepatide 15 mg)
- 84 weeks, open-label comparison
- CagriSema: 23% weight loss
- Did not achieve non-inferiority versus tirzepatide 15 mg - tirzepatide performed better
- This is an important result: CagriSema is powerful, but Zepbound remains the current injectable benchmark
High-dose CagriSema (planned)
Novo Nordisk is also testing a higher-dose formulation (2.4 mg/7.2 mg) with Phase 3 trials planned to start in H2 2026. The higher dose may produce even stronger results.
How does CagriSema compare to other drugs?
| Drug | Mechanism | Status | Avg. weight loss |
|---|---|---|---|
| Wegovy 2.4 mg | GLP-1 | ✅ Approved | ~15–17% |
| Zepbound 15 mg | GIP + GLP-1 | ✅ Approved | ~21% |
| CagriSema 2.4/2.4 mg | Amylin + GLP-1 | FDA review | 22.7–23% |
| Wegovy HD 7.2 mg | GLP-1 | ✅ Approved | ~21% |
CagriSema sits between Zepbound and the emerging pipeline drugs in terms of weight loss efficacy, and it introduces a genuinely novel mechanism (amylin + GLP-1) not currently available in any approved drug.
What are the side effects?
Side effects in the REDEFINE trials were primarily gastrointestinal - consistent with the semaglutide component:
- Nausea
- Diarrhea
- Vomiting
- Constipation
The majority were mild to moderate and diminished over time. CagriSema also showed additional cardiovascular benefits in the trials: reduced blood pressure and anti-inflammatory effects.
When will CagriSema be available?
The NDA was submitted to the FDA on December 18, 2025. A standard FDA review takes approximately 10–12 months, which would put a potential approval decision in late 2026.
Final takeaway
CagriSema combines semaglutide with a new amylin analogue to produce significantly stronger weight loss than semaglutide alone. It is in FDA review following a December 2025 submission, with potential approval in late 2026. If approved, it will be the first drug ever to combine GLP-1 and amylin mechanisms - and the first genuinely new obesity drug mechanism in years.
Consult your healthcare provider before making any treatment decisions based on pipeline data.
Sources
- CagriSema FDA history: drugs.com/history/cagrisema.html
- REDEFINE 1 results: Novo Nordisk press release, December 20, 2024
- REDEFINE 2 results: Novo Nordisk press release, March 10, 2025
- REDEFINE 4 results: Novo Nordisk press release, February 23, 2026
- NDA submission announcement: Novo Nordisk, December 18, 2025
FAQ
What is CagriSema?
CagriSema is a once-weekly injectable combination of cagrilintide (2.4 mg, an amylin analogue) and semaglutide (2.4 mg, a GLP-1 agonist) developed by Novo Nordisk. It is not yet FDA approved - an NDA was submitted in December 2025 and FDA review is expected in 2026.
How much weight does CagriSema cause you to lose?
The REDEFINE 1 Phase 3 trial showed 22.7% average weight loss at 68 weeks in adults with obesity - significantly more than semaglutide alone (16.1%) or cagrilintide alone (11.8%) in the same trial.
What is cagrilintide?
Cagrilintide is a long-acting analogue of amylin, a hormone secreted by the pancreas alongside insulin after eating. Amylin reduces appetite, slows gastric emptying, and suppresses glucagon through different brain pathways to GLP-1. Combining both creates a stronger and more complementary appetite effect.
Is CagriSema better than Wegovy?
In the REDEFINE 1 trial, CagriSema produced 22.7% weight loss vs 16.1% for semaglutide 2.4 mg alone - a meaningful difference. In REDEFINE 4, CagriSema produced 23% weight loss but did not achieve non-inferiority versus tirzepatide 15 mg (Zepbound), which performed better.
When will CagriSema be available?
Novo Nordisk submitted the NDA to the FDA in December 2025. FDA review is expected during 2026. Approval could come in late 2026 if the review proceeds smoothly.